006280 — GC Biopharma Cashflow Statement
0.000.00%
- KR₩1tn
- KR₩2tn
- KR₩2tn
- 25
- 39
- 41
- 24
Annual cashflow statement for GC Biopharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 89,271 | 136,950 | 69,415 | -19,809 | -42,637 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -2,981 | -21,276 | 47,204 | 79,765 | 91,151 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -99,107 | -45,599 | -62,561 | -141,328 | -183,008 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 35,974 | 125,979 | 119,154 | -5,473 | -53,460 |
Capital Expenditures | -101,395 | -123,539 | -94,690 | -125,992 | -42,391 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 131,079 | -8,539 | -110,569 | -24,252 | -25,503 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 29,684 | -132,077 | -205,259 | -150,243 | -67,894 |
Financing Cash Flow Items | 11,325 | -42,611 | 146 | 1,308 | -161 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 80,987 | -41,270 | -2,481 | 100,512 | 93,845 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 133,827 | -46,228 | -80,694 | -55,660 | -27,143 |